Search
Search Results
-
Prognostic value of elastic lamina staining in patients with stage III colon cancer
ObjectiveThe objectives of this study were to analyze the difference between the preoperative radiological and postoperative pathological stages of...
-
Sleep and cancer recurrence and survival in patients with resected Stage III colon cancer: findings from CALGB/SWOG 80702 (Alliance)
BackgroundWe sought to assess the influences of sleep duration, sleep adequacy, and daytime sleepiness on survival outcomes among Stage III colon...
-
The prognostic and predictive significance of perineural invasion in stage I to III colon cancer: a propensity score matching-based analysis
BackgroundColorectal cancer (CRC) presents with varying prognoses, and identifying factors for predicting metastasis and outcomes is crucial....
-
Rural versus urban commuting patients with stage III colon cancer: is there a difference in treatment and outcome?
BackgroundTo evaluate if there are differences in outcomes for patients with stage III colon cancer in those from urban vs. rural commuting areas.
...
-
Clinical characteristics and prognosis analysis of postoperative patients with stage I–III colon cancer based on SEER database
PurposeTo identify the relevant factors affecting the prognosis and survival time of colon cancer and construct a survival prediction model.
...
-
Variations in the Type of Adjuvant Chemotherapy Among Stage III Colon Cancer Patients in England
PurposeTreatment with any adjuvant chemotherapy for stage III colon cancer has been shown to differ between population groups. Few studies, however,...
-
mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial
BackgroundHigh-risk stage III colon cancer has a considerably poorer prognosis than stage II and low-risk stage III colon cancers. Nevertheless, most...
-
Adjuvant Chemotherapy Is Associated with Improved Survival for Stage III Colon Cancer When Initiated Beyond 8 Weeks
BackgroundThe National Comprehensive Cancer Network (NCCN) guidelines recommend adjuvant chemotherapy (AC) within 6–8 weeks of surgical resection for...
-
Clinical utility of the carcinoembryonic antigen level in patients with stage III colon cancer after surgery and adjuvant chemotherapy
PurposeThe association between perioperative and post-adjuvant carcinoembryonic antigen (CEA) levels and recurrence and prognosis remains unclear. We...
-
Conditional survival analysis and real-time prognosis prediction in stage III T3–T4 colon cancer patients after surgical resection: a SEER database analysis
BackgroundConditional survival (CS) takes into consideration the duration of survival post-surgery and can provide valuable additional insights. The...
-
Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review
ObjectiveThe aims of this study was to appraise the health economic evidence for adjuvant chemotherapy (AC) strategies in stage II and III colon...
-
Stage II Colon Cancer: Towards an Individualized Treatment Approach
The decision on whether to administer adjuvant chemotherapy in stage II colon cancer continues to be an ongoing debate. There are no clear-cut...
-
A prognostic nomogram for predicting recurrence-free survival of stage I–III colon cancer based on immune-infiltrating Treg-related genes
PurposeA high postoperative recurrence rate seriously impedes colon cancer (CC) patients from achieving long-term survival. Here, we aimed to develop...
-
Preoperative albumin–bilirubin score as a prognostic indicator in patients with stage III colon cancer
The albumin–bilirubin (ALBI) score was created to assess the severity of liver dysfunction and to predict prognosis of hepatocellular carcinoma....
-
Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen
We evaluate the prognostic value of chemotherapy and other prognostic factors on overall survival among colon patients with deficient mismatch...
-
Lymphovascular invasion represents a superior prognostic and predictive pathological factor of the duration of adjuvant chemotherapy for stage III colon cancer patients
BackgroundLymphovascular invasion (LVI) and perineural invasion (PNI) can indicate poor survival outcomes in colorectal cancer, but few studies have...
-
The effects of chemotherapy, primary tumor location and histological subtype on the survival of stage III colon cancer patients
ObjectiveColon cancer (CC) is one of the most common cancers worldwide and has a poor prognosis. Surgery followed by adjuvant chemotherapy is the...
-
The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data
ObjectiveColorectal cancer is common worldwide, and adjuvant treatment’s benefit is still controversial. We designed this study to determine the role...
-
Enhanced Clinical Utility of Molecular Budding Signature as a Recurrence Risk Determinant in Stage II and III Colon Cancer Patients
BackgroundA molecular budding signature (MBS), which consists of seven tumor budding-related genes, was recently presented as a prominent prognostic...
-
Effects of deficient mismatch repair on the prognosis of patients with stage II and stage III colon cancer during different postoperative periods
BackgroundWe evaluated the prognostic role of deficient mismatch repair (dMMR) systems in stage II and stage III colon cancer patients during...
